OSE given green light to continue NSCLC trial

3 July 2018

French company OSE Immunotherapeutics (Euronext: OSE) is cracking on with its Atalante 1 Phase III trial of Tedopi for the treatment of non-small cell lung cancer (NSCLC) patients who have not responded to immune checkpoint inhibitors.

An Independent Data Monitoring Committee (IDMC) gave a positive recommendation for the company to continue the trial following a review of existing data. Tedopi is being compared to chemotherapy in the trial, the primary endpoint of which is overall survival.

"Our Tedopi neoepitope product is well-positioned to benefit NSCLC patients experiencing treatment failure after checkpoint inhibitors"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK